Comment & Analysis

Amgen’s agreement with RNA interference specialist Arrowhead Pharmaceuticals will see it develop ...

Early data from the phase IIa trial of Arbutus’s hepatitis B RNA interference therapy ARB-1467 are ...

Welcome to your weekly digest of approaching regulatory and clinical readouts. By the end of the ...

MedTech

EventAnalyzer

Therapeutic Focus

Market Moving Events

EP Vantage Interviews